Intrance Holdings

Intrance Holdings is a Sweden-based life sciences holding company associated with Intrance Medical Systems, its U.S.-based operating subsidiary focused on advanced Parkinson's disease. The group is developing and commercializing a drug-device therapy centered on Lecigon, a fixed-dose intestinal infusion gel containing levodopa, carbidopa, and entacapone delivered through a wearable pump. The company has positioned the asset for markets including the U.S., Canada, Latin America, Japan, and Taiwan, while rights in much of Europe were commercialized separately. Intrance received FDA clearance of its IND in 2024 and disclosed a pivotal pharmacokinetic study, INT-001, in 2025. The business appears focused primarily on a single late-development neurology program rather than a broad multi-asset platform.